Targeting proteases involved in the viral replication of SARS-CoV-2 by sesquiterpene lactones from chicory (Cichorium intybus L.).
暂无分享,去创建一个
D. Bosch | K. Cankar | João P Baixinho | Cláudia Nunes dos Santos | M. A. Ávila-Gálvez | José D Anastácio | N. Fernández | Carlos Rafael-Pita
[1] Hao Tan,et al. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease , 2022, Journal of medicinal chemistry.
[2] M. Kumar,et al. Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies , 2022, Frontiers in Microbiology.
[3] D. Komander,et al. Inhibitors of SARS-CoV-2 PLpro , 2022, Frontiers in Chemistry.
[4] U. Rova,et al. Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds , 2022, Computational and Structural Biotechnology Journal.
[5] K. Murakami,et al. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay , 2022, Communications Biology.
[6] Haihai Jiang,et al. Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone , 2022, Frontiers in Chemistry.
[7] A. Babaei,et al. Artemisinins in Combating Viral Infections Like SARS-CoV-2, Inflammation and Cancers and Options to Meet Increased Global Demand , 2022, Frontiers in Plant Science.
[8] T. Brás,et al. Anti-Inflammatory and Immunoregulatory Action of Sesquiterpene Lactones , 2022, Molecules.
[9] M. Pinheiro,et al. SARS-CoV-2 introductions and early dynamics of the epidemic in Portugal , 2022, Communications Medicine.
[10] A. Jamal,et al. Antiviral Effects of Artemisinin and Its Derivatives against SARS-CoV-2 Main Protease: Computational Evidences and Interactions with ACE2 Allelic Variants , 2022, Pharmaceuticals.
[11] Ri-lei Yu,et al. Design of SARS-CoV-2 Mpro, PLpro dual-target inhibitors based on deep reinforcement learning and virtual screening , 2021, Future medicinal chemistry.
[12] A. Capriotti,et al. Characterization of the Trans-Epithelial Transport of Green Tea (C. sinensis) Catechin Extracts with In Vitro Inhibitory Effect against the SARS-CoV-2 Papain-like Protease Activity , 2021, Molecules.
[13] Malina A. Bakowski,et al. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 , 2021, Nature Communications.
[14] S. Durdağı,et al. Instant determination of the artemisinin from various Artemisia annua L. extracts by LC‐ESI‐MS/MS and their in‐silico modelling and in vitro antiviral activity studies against SARS‐CoV‐2 , 2021, Phytochemical analysis : PCA.
[15] K. Oksman-Caldentey,et al. Chicory Extracts and Sesquiterpene Lactones Show Potent Activity against Bacterial and Fungal Pathogens , 2021, Pharmaceuticals.
[16] K. Gajiwala,et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 , 2021, Science.
[17] R. Preissner,et al. Reynoutria Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors–Molecular Docking and In Vitro Study , 2021, Pharmaceuticals.
[18] F. Abas,et al. Bioactivities of Phenolic Compounds from Kiwifruit and Persimmon , 2021, Molecules.
[19] C. Santos,et al. Sesquiterpene Lactones: Promising Natural Compounds to Fight Inflammation , 2021, Pharmaceutics.
[20] M. Plazas,et al. Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity , 2021, Foods.
[21] D. Bosch,et al. Supercritical CO2 Extraction as a Tool to Isolate Anti-Inflammatory Sesquiterpene Lactones from Cichorium intybus L. Roots , 2021, Molecules.
[22] F. Apone,et al. Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (in vitro): A Promising Source of Novel Antiviral Drugs , 2021, Frontiers in Chemistry.
[23] Arpit Shukla,et al. Identifying structural–functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation , 2021, Molecular diversity.
[24] T. Jin,et al. Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease , 2021, Frontiers in Chemistry.
[25] L. Palese,et al. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome , 2021, Molecules.
[26] Lijun Rong,et al. Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases , 2021, Cell & Bioscience.
[27] N. Ghosh,et al. Inhibitory efficacy of RNA virus drugs against SARS-CoV-2 proteins: An extensive study , 2021, Journal of Molecular Structure.
[28] A. Morice,et al. Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? , 2021, Lung.
[29] Leiliang Zhang,et al. Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors , 2020, Biochemical and Biophysical Research Communications.
[30] S. Kumari,et al. Structural insights into SARS-CoV-2 proteins , 2020, Journal of Molecular Biology.
[31] Qin Xu,et al. Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial , 2020, International Journal of Antimicrobial Agents.
[32] B. Luan,et al. Targeting Proteases for Treating COVID-19 , 2020, Journal of proteome research.
[33] Nayim Sepay,et al. Anti-COVID-19 terpenoid from marine sources: A docking, admet and molecular dynamics study , 2020, Journal of Molecular Structure.
[34] Cooper A. Taylor,et al. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors , 2020, Nature Communications.
[35] Chia-en A. Chang,et al. Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease , 2020, Frontiers in Molecular Biosciences.
[36] Zhìhóng Hú,et al. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro , 2020, ACS infectious diseases.
[37] G. Hummer,et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity , 2020, Nature.
[38] D. Moreno,et al. Chicory (Cichorium intybus L.) as a food ingredient - Nutritional composition, bioactivity, safety, and health claims: A review. , 2020, Food chemistry.
[39] Chunlong Ma,et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease , 2020, Cell Research.
[40] A. Joachimiak,et al. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography , 2020, Nature Communications.
[41] D. Lorne Tyrrell,et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication , 2020, Nature Communications.
[42] R. Hilgenfeld,et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors , 2020, Science.
[43] Cynthia Liu,et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases , 2020, ACS central science.
[44] W. Ko,et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges , 2020, International Journal of Antimicrobial Agents.
[45] Yu Wai Chen,et al. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like Protease (3CLpro) Structure: Virtual Screening Reveals Velpatasvir, Ledipasvir, and Other Drug Repurposing Candidates , 2020 .
[46] W. Liu,et al. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV , 2020, Chembiochem : a European journal of chemical biology.
[47] Zi-feng Yang,et al. Inhibition of influenza virus via a sesquiterpene fraction isolated from Laggera pterodonta by targeting the NF-κB and p38 pathways , 2017, BMC Complementary and Alternative Medicine.
[48] Haiyang Liu,et al. Lindenane sesquiterpenoid dimers from Chloranthus japonicus inhibit HIV-1 and HCV replication. , 2016, Fitoterapia.
[49] Lijia Yang,et al. Sesquiterpenes from the fruits of Illicium jiadifengpi and their anti-hepatitis B virus activities. , 2015, Fitoterapia.
[50] A. Mesecar,et al. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds , 2014, Antiviral Research.
[51] C. Lopes,et al. Sesquiterpene lactones: Adverse health effects and toxicity mechanisms , 2013, Critical reviews in toxicology.
[52] C. Wagstaff,et al. Sesquiterpenoids Lactones: Benefits to Plants and People , 2013, International journal of molecular sciences.
[53] K. Park,et al. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases , 2012, Bioorganic & Medicinal Chemistry.
[54] F. Tsai,et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds , 2005, Antiviral Research.
[55] Po-Huang Liang,et al. Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3′-digallate (TF3) , 2005, Evidence-based complementary and alternative medicine : eCAM.
[56] C. Lipinski. Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.
[57] Eric D. Brown,et al. High-Throughput Screening Identifies Inhibitors of the SARS Coronavirus Main Proteinase , 2004, Chemistry & Biology.
[58] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.